Preserved Sensitivity to $\beta_2$-Adrenergic Receptor Agonists in Patients with Type 1 Diabetes Mellitus and Hypoglycemia Unawareness

Bastiaan E. De Galan, Pieter De Mol, Lianne Wennekes, Bas J. J. Schouwenberg, and Paul Smits

Departments of General Internal Medicine (B.E.D.G., B.J.J.S., P.S.) and Pharmacology-Toxicology (P.D.M., L.W., P.S.), Radboud University Nijmegen Medical Centre, 6500 HB, Nijmegen, The Netherlands

**Background and Objective:** Use of $\beta_2$-adrenergic receptor agonists has been advocated for the treatment of hypoglycemia unawareness in type 1 diabetes. In vitro, however, hypoglycemia unawareness has been associated with reduced $\beta_2$-adrenergic sensitivity. Therefore, in vivo sensitivity to $\beta_2$-adrenergic receptor agonist stimulation was compared between type 1 diabetic patients with and without hypoglycemia unawareness and nondiabetic controls.

**Methods:** Ten type 1 diabetic patients with hypoglycemia unawareness, 12 type 1 diabetic patients with intact hypoglycemic awareness, and 11 healthy controls were enrolled. $\beta_2$-Adrenergic sensitivity was determined by measuring the forearm vasodilator response to intravenous infusion of salbutamol. Salbutamol was infused in six increasing doses ranging from 0.003 to $1.0 \mu g \cdot ml^{-1} \cdot min^{-1}$. Forearm blood flow (FBF) was bilaterally measured by venous occlusion plethysmography. Diabetic patients received low-dose insulin before FBF measurements to ensure that experiments were carried out under normoglycemic conditions.

**Results:** At baseline, FBF was $1.9 \pm 0.3 ml \cdot min^{-1} \cdot dl^{-1}$ in controls, $2.3 \pm 0.4 ml \cdot min^{-1} \cdot dl^{-1}$ in patients with intact awareness, and $1.4 \pm 0.1 ml \cdot min^{-1} \cdot dl^{-1}$ in patients with hypoglycemia unawareness ($P = 0.048$ vs. aware patients). In response to salbutamol, FBF increased 9.1-fold in controls, 8.0-fold in patients with intact awareness, and 10.7-fold in patients with hypoglycemia unawareness ($P = 0.048$ vs. aware patients). Heart rate increased in all groups due to systemic spillover of salbutamol but appeared blunted, considering a greater fall in mean arterial pressure in patients with hypoglycemia unawareness.

**Conclusions:** Sensitivity to $\beta_2$-adrenergic receptor agonist stimulation is preserved in type 1 diabetic patients with hypoglycemia unawareness.

There is evidence from in vitro studies that the reduced $\beta_2$-adrenergic sensitivity associated with hypoglycemia unawareness is mediated through the $\beta_2$-adrenergic receptor. In hypoglycemia-unaware T1DM patients with a reduced chronotropic response to iv isoproterenol, $\beta_2$-adrenergic receptors on mononuclear leukocytes were found to express reduced affinity for isoproterenol (9). In another study, 1 wk of intensive insulin treatment reduced $\beta_2$-adrenoceptor density on lymphocytes in T1DM, the magnitude of which correlated highly with the number of hypoglycemic events and with loss of hypoglycemic awareness (10). These data contrast with an in vivo study investigating the effect of local perfusion with terbutaline, a $\beta_2$-adrenergic agonist, through a microdialysis catheter (11). In that study, terbutaline-induced lipolysis and stimulation of adipose tissue blood flow were not found to differ between intensively treated (presumably hypoglycemia unaware) T1DM patients and control subjects. However, blood flow was assessed indirectly, using a model that can be applied only under the assumption of steady-state conditions (12).

Other than by in vitro (9, 10) or indirect (11) assessment, the sensitivity of the $\beta_2$-adrenergic receptor has not been tested quantitatively in T1DM with hypoglycemia unawareness by a validated in vivo technique. The purpose of the present study was to compare $\beta_2$-adrenergic sensitivity in vivo in T1DM patients with hypoglycemia unawareness to that in T1DM patients with normal hypoglycemic awareness and nondiabetic controls. To quantify $\beta_2$-adrenergic sensitivity, we measured the vasodilator action of salbutamol, a selective $\beta_2$-adrenergic receptor agonist, using the perfused forearm technique (13).
Subjects and Methods

Written informed consent was obtained from 22 T1DM patients recruited from the outpatient clinic of our hospital and 11 healthy controls recruited by advertisement. All diabetic subjects were free of classical long-term diabetic complications, except for background retinopathy. Autonomic neuropathy was excluded by normal responses to cardiovascular reflex tests (i.e. heart rate response to Valsalva maneuver, heart rate variability to deep breathing, and blood pressure responses to standing up and sustained handgrip) (14). The magnitude of hypoglycemic awareness was assessed on the basis of the score on a Dutch modification of a standardized hypoglycemia questionnaire (15). Patients with a score less than 3 (of maximal 10) were classified as being hypoglycemia unaware (n = 12), and patients with higher scores were classified as hypoglycemia unaware (n = 10). Three of the latter had previously participated in a trial in which their inability to detect hypoglycemia was objectified by a hypoglycemic clamp test (16). All participants had a normal blood pressure and used no medication other than insulin or oral contraceptives, except for one nondiabetic and one participant (i.e., one in the control group and two in each of the diabetic groups). All participants were requested to abstain from caffeine-containing substances and smoking for at least 48 h, from alcohol for at least 24 h, and from food intake at least 10 h before experiments took place. Diabetic subjects were asked to perform blood glucose self-measurements at least four times per day for at least 5 d preceding the experiment and to reduce the bedtime insulin dose by 20% on the preceding day to avoid nocturnal hypoglycemia. All patients checked capillary glucose at approximately 0200 h, and in case of nocturnal hypoglycemia, the test was canceled or postponed. The Radboud University Nijmegen Medical Centre Medical Ethics Committee approved the study.

Procedure

All experiments took place in the morning in a quiet, temperature-controlled room (23–24 °C), with the subjects supine. The brachial artery of the nondominant arm was cannulated (Angiocath 20-gauge; Beckton Dick-inson, Sandy, UT) under local anesthesia (Xylocaine 2%) for infusion of salbutamol (Ventolin; GlaxoSmithKline, Zeist, The Netherlands) and blood pressure monitoring (monitor 378341A; Hewlett Packard GmbH, Böblingen, Germany). Intraarterial infusion rates were calculated per deciliter arm volume, measured by water displacement. In the diabetic subjects, an antecubital vein of the contralateral arm was cannulated for administration of insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark) and glucose 20% (if necessary). After cannulation(s), a 30-min equilibration period was allowed to pass before baseline variables were obtained. A low-dose IV insulin infusion of 7–10 mU/min body surface area was initiated to obtain normoglycemia in the diabetic subjects. Because of insulin’s (modest) vasodilator effect (17), the insulin infusion was terminated as soon as plasma glucose levels fell to less than 7.0 mmol/liter; glucose 20% was given as necessary to prevent hypoglycemia.

The ensuing experimental procedure was similar for all participants. At constant flow rates, 5-min infusions of saline and incremental doses of salbutamol diluted in saline vehicle (0.003, 0.01, 0.02, 0.03, 0.1, 0.2, 1.0 µg/min; 7 ml/1 min) were subsequently administered intraarterially. Forearm blood flow (FBF) was measured during the final 2 min of each dosing step in both arms, using electrocardiogram-triggered mercury-in-silastic (Dow Corning, Midland, MI) strain gauge venous occlusion plethysmography, as described previously (13). The mean of six to eight calculations for statistical analyses

Calculations and statistical analyses

Vasodilator responses to salbutamol were expressed as absolute FBF and as increase in FBF above baseline values (ΔFBF). The effects of salbutamol on FBF and hemodynamic variables were analyzed by repeated-measures ANOVA. Differences in means were tested by Student’s t test. For data that had no normal distribution, the Wilcoxon signed rank test and Mann-Whitney U test were used to compare paired and unpaired data, respectively. The χ2 test was used to compare the male-female distribution of the study population. The SPSS personal computer software package (version 12.0; SPSS, Chicago, IL) was used for statistical analyses. P < 0.05 was considered statistically significant. Data are presented as means ± SEM unless otherwise specified.

Results

Characteristics of the participants are shown in Table 1. As a group, the diabetic patients were slightly older and had higher heart rate and blood pressure at baseline than the control subjects. There was a preponderance of males among the unaware diabetic patients and a preponderance of females among the awake diabetic patients, but this difference did not reach statistical significance. HbA1c and fasting plasma glucose values were lower and disease duration was longer in T1DM patients with hypoglycemia unawareness, compared with patients with intact awareness. Insulin levels were significantly higher in diabetic patients than controls at all time points (Table 2) but despite intermittent insulin infusion remained relatively stable for the duration of the experiment. Plasma glucose levels, albeit significantly higher than in controls, remained around the upper value for the normoglycemic range in the diabetic patients during FBF measurements.

The vascular response to salbutamol

Baseline values for FBF in the infusion arm were 1.9 ± 0.3 ml/min · 10−3 dm−2 min−1 in control subjects, 2.3 ± 0.4 ml/min · 10−3 dm−2 min−1 in hypoglycemia-aware T1DM patients (P = NS), and 1.4 ± 0.1 ml/min · 10−3 dm−2 min−1 in hypoglycemia-unaware patients (P = 0.048 vs. aware patients). Corresponding values in the noninfused arm were 1.9 ± 2.0, 2.0 ± 0.2, and 1.6 ± 0.2 ml/min · 10−3 dm−2 min−1 (P = NS). The lowering of plasma glucose levels in the diabetic patients did not affect FBF in either arm (data not shown). Maximal FBF responses to salbutamol in the infused arm were 14.9 ± 1.3 ml/min · 10−3 dm−2 min−1 in controls, 14.6 ± 1.3 ml/min · 10−3 dm−2 min−1 in hypoglycemia-aware diabetic patients, and 13.8 ± 1.5 ml/min · 10−3 dm−2 min−1 in hypoglycemia-unaware diabetic patients (Fig. 1), corresponding to 9.1-, 8.0-, and 10.7-fold increases, respectively (P < 0.001 for all groups). There were no statistically significant differences between the groups for

### Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>T1DM aware</th>
<th>T1DM unaware</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. (male/female)</td>
<td>11 (6/5)</td>
<td>12 (4/8)</td>
<td>10 (7/3)</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>28.3 ± 8.1</td>
<td>33.3 ± 11.5</td>
<td>38.8 ± 9.7a</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.2 ± 2.5</td>
<td>25.0 ± 1.9</td>
<td>23.8 ± 2.3</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>85 ± 5</td>
<td>69 ± 9</td>
<td>61 ± 9</td>
</tr>
<tr>
<td>MAP (mm Hg)</td>
<td>79 ± 11</td>
<td>90 ± 9</td>
<td>95 ± 11a</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>ND</td>
<td>8.7 ± 1.2</td>
<td>7.6 ± 0.7ab</td>
</tr>
<tr>
<td>Duration of diabetes (yr)</td>
<td>11.6 ± 5.2</td>
<td>19.7 ± 6.2b</td>
<td></td>
</tr>
<tr>
<td>Insulin dose (U/kg)</td>
<td>0.72 ± 0.24</td>
<td>0.68 ± 0.17</td>
<td></td>
</tr>
</tbody>
</table>

Data are in number or means ± SD. ND, Not determined.

a P < 0.05 vs. controls.

b P < 0.05 vs. T1DM aware.
TABLE 2. Plasma glucose and insulin levels

<table>
<thead>
<tr>
<th>Glucose level (mg/dl)</th>
<th>Controls</th>
<th>T1DM aware</th>
<th>T1DM unaware</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>92 ± 8</td>
<td>243 ± 72a</td>
<td>211 ± 42ab</td>
</tr>
<tr>
<td>Prior to test</td>
<td>92 ± 8</td>
<td>108 ± 16a</td>
<td>111 ± 17a</td>
</tr>
<tr>
<td>End of test</td>
<td>92 ± 8</td>
<td>125 ± 21a</td>
<td>131 ± 29a</td>
</tr>
<tr>
<td>Insulin level (µU/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>9 ± 4</td>
<td>30 ± 43a</td>
<td>30 ± 20a</td>
</tr>
<tr>
<td>Prior to test</td>
<td>13 ± 5</td>
<td>27 ± 14a</td>
<td>29 ± 17a</td>
</tr>
<tr>
<td>End of test</td>
<td>10 ± 4</td>
<td>21 ± 12a</td>
<td>21 ± 14a</td>
</tr>
</tbody>
</table>

Data are means ± sd. To convert plasma glucose values to milligrams per liter, divide by 18; to convert plasma insulin values to picomoles per liter, multiply by 6.

P < 0.05 vs. controls.

P < 0.05 vs. T1DM aware.

either the maximal FBF response or the course of FBF (P = 0.7 by ANOVA). Comparable results were obtained when the data were expressed as absolute or relative changes in FBF from baseline (AFBF).

In both controls and hypoglycemia-aware T1DM patients, FBF in the noninfused arm increased 1.5-fold in response to the highest salbutamol dose to 3.0 ± 0.6 ml min⁻¹ dl⁻¹ and 2.6 ± 0.3 ml min⁻¹ dl⁻¹ in the first (P = 0.007) and 0.4 to 13.1 ml min⁻¹ dl⁻¹ in the latter (P = 0.043), indicating a systemic effect. In T1DM patients with hypoglycemia unawareness, salbutamol did not affect FBF in the noninfused arm. Heart rate increased by 13 ± 2, 11 ± 2, and 9 ± 2 beats per minute (bpm) in controls, hypoglycemia-aware, and hypoglycemia-unaware T1DM patients, respectively (P < 0.001 for all groups), whereas mean arterial pressure (MAP) decreased in unaware diabetic patients (−5 ± 3 mm Hg, P = 0.001) and controls (−3 ± 2 mm Hg, P = 0.005) but not in patients with intact awareness. Despite within-group effects, the course of FBF in the noninfused arm and heart rate and MAP did not differ among the three groups when tested by ANOVA.

Stratification according to glycemic control and duration of disease

Stratification of the diabetic patients (n = 22) according to HbA1c value yielded a low-HbA1c group [mean HbA1c 7.1% (range 6.0–7.9), n = 8], a middle-HbA1c group [8.1% (8.0–8.3%), n = 7], and a high-HbA1c group [9.5% (8.7–11.4%), n = 7]. In response to salbutamol, FBF increased from 1.7 ± 0.5 to 13.5 ± 1.4 ml min⁻¹ dl⁻¹ in the low-HbA1c group, from 1.6 ± 0.3 to 14.0 ± 2.0 ml min⁻¹ dl⁻¹ in the middle-HbA1c group, and from 2.4 ± 0.5 to 15.3 ± 1.7 ml min⁻¹ dl⁻¹ in the high-HbA1c group (P = NS by ANOVA). When recalculating FBF responses according to disease duration, FBF increased from 1.9 ± 0.3 to 15.4 ± 1.3 ml min⁻¹ dl⁻¹ in patients with a mean disease duration of 9.9 (range 3–15) yr and from 1.9 ± 0.4 to 13.1 ± 1.4 ml min⁻¹ dl⁻¹ in patients with a mean disease duration of 20.6 (17–33) yr (P = NS by ANOVA).

Discussion

Reduced β-adrenergic sensitivity has been reported in T1DM patients with hypoglycemia unawareness (9, 10). The present study was conducted to test the involvement of the β₂-adrenergic receptor in vivo. Therefore, the vasodilator response to local administration of salbutamol was compared among T1DM patients with hypoglycemia unawareness, T1DM patients with intact hypoglycemic awareness, and nondiabetic controls. Our finding of similar vasodilator responses does not support a role for the β₂-adrenergic receptor in reduced β-adrenergic sensitivity. When the data were expressed as fold increase from baseline, salbutamol elicited even higher responses in unaware diabetic patients than the other two groups, although these differences did not reach statistical significance.

Our data extend those obtained previously with microdialysis (11) but are at variance with in vitro studies reporting reduced β₂-adrenergceptor-mediated action in hypoglycemia-unaware T1DM patients on basis of reduced β₂-adrenergic receptor density or affinity for isoproterenol on white blood cells (9, 10). However, alterations in β₂-adrenergceptor density or binding affinity on white blood cells do not necessarily reflect those on other tissues, such as the vascular wall. In addition, white blood cells may not be a stable population, especially after stress hormone release. Lymphocytes, granulocytes, and monocytes of various subsets that differ according to receptor density and binding affinity from cells already in the circulation can be mobilized by catecholamines and cortisol (18). In contrast, the perfused forearm technique is a validated in vivo method to quantify tissue sensitivity to vasoactive substances (10). Moreover, our findings remained unaltered when the diabetic patients were stratified according to tightness of glycemic control as crude marker of (the risk for) hypoglycemia unawareness.

It is unlikely that the higher insulin levels in the two diabetic groups affected our data. First, a significant vasodilator effect of insulin requires 4-fold higher plasma concentrations than those achieved here (17); second, insulin does not exert its vasodilator effects by modulation of β-adrenergic receptors (19). Moreover, insulin levels were identical in the two diabetic groups throughout the experiments, and baseline FBF, although mutually different, was not dissimilar from that in controls.

Our study had some limitations. First of all, the groups were incompletely matched for sex, age, and disease duration. The effect of the latter two parameters on β₂-adrenergic

![Graph](image)
sensitivity is probably negligible: vasodilator responses to β-adrenergic stimulation are age independent (20), and stratification of our data according to disease duration did not reveal an effect of diabetes per se. However, β₂-adrenergic sensitivity may differ by sex, with women probably having a more profound responsiveness to β₂-adrenergic stimulation than men (21). In the present study, women were overrepresented in the hypoglycemia-aware diabetic group and underrepresented in the unaware diabetic group, although this difference did not reach statistical significance. A post hoc analysis of our data by gender did not reveal differences in β₂-adrenergic sensitivity between men and women in either the control or diabetic group or when all subjects were pooled (data not shown), although it should be acknowledged that our study was not designed for that purpose. Yet even when gender would have had an effect, a more balanced matching according to gender would have resulted in greater, not smaller, salbutamol responsiveness in the T1DM patients with hypoglycemia unawareness.

Previous in vivo studies on β-adrenergic sensitivity in diabetes used the isoproterenol sensitivity test (4–6), in which β-adrenergic sensitivity is expressed as the dose of iv isoproterenol that produces an increment in heart rate of 25 bpm over baseline values. This heart rate increment is the consequence of direct stimulation of cardiac β₁- (and β₂-) adrenoceptors and an indirect baroreflex response to β₂-adrenoceptor-mediated peripheral vasodilatation (22). When reconciling data from studies using the isoproterenol test with that of the current study, it seems plausible that hypoglycemia-associated reduction in β-adrenergic sensitivity is mediated by the β₁-adrenergic receptor. In our study, the heart rate response to systemic spillover of salbutamol in T1DM patients with hypoglycemia unawareness appeared blunted in view of the greater fall in blood pressure, which lends support to this suggestion. However, subtle impairments in baroreflex sensitivity, only to be detected by spectral analysis (23, 24) but not by conventional tests, have been found to correlate with diabetes duration. Because disease duration was longer in patients with hypoglycemia unawareness, compared with patients with intact awareness in both the current study and studies using the isoproterenol test (4–6), a contribution of reduced baroreflex sensitivity to the lower heart rate response cannot be excluded.

In conclusion, sensitivity to β₂-adrenergic agonist stimulation is not reduced in T1DM patients with hypoglycemia unawareness. This observation may be of potential value when treatment with β₂-adrenergic agonists is considered to support glucose counterregulation. Whether reduced β₂-adrenergic sensitivity in hypoglycemia unawareness is mediated through the β₁-adrenergic receptor or impairments in the baroreflex response pathway requires further study.

Acknowledgments

We are indebted to all participants for their cooperation in the study.

Received March 8, 2006. Accepted May 8, 2006.

Address all correspondence and requests for reprints to: Bastiaan E. De Galan, M.D., Ph.D., Department of General Internal Medicine 463, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. E-mail: b.degalan@lumc.nl.

The authors have nothing to disclose and no conflicts of interest.

References


JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.